News & blog
Dechra In £139M Drug Developer Swoop
Dechra Pharmaceuticals has acquired a drug developer for $200m (£139m), part-funded by a £47.1m share issue, in a deal that significantly strengthens its position in the US.
The Northwich-headquartered veterinary pharmaceutical business has announced the conditional acquisition of Putney, a Maine-based developer of generic companion animal pharmaceuticals. The £139m consideration is payable in cash on completion. Read More
17th March 2016Northern Gateway partnership launches investment opportunities arising from HS2 at MIPIM